ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Howard M. Sandler, MD, and Christopher Sweeney, MBBS, on Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discuss the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).

Cost of Care

Leonard Saltz, MD

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.

Lung Cancer

Palliative Care

Symptom Management

Charles F. von Gunten, MD, PhD

Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care

Charles F. von Gunten, MD, PhD, of OhioHealth Kobacker House discusses the ROMANA 1 and 2 trials on cachexia in NSCLC and a study on olanzapine vs fosaprepitant for the prevention of nausea and vomiting (Abstracts 9500 and 9502).

Leukemia

Lymphoma

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD, on Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

James O. Armitage, MD, of the University of Nebraska Medical Center, and Asher Alban Akmal Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discuss an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).

Palliative Care

Lung Cancer

Survivorship

Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM

Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care

Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, and Areej El-Jawahri, MD, of Massachusetts General Hospital, discuss two important studies on early palliative care and the use of anamorelin in advanced NSCLC with cachexia.

May

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Howard M. Sandler, MD, and Christopher Sweeney, MBBS, on Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD, on Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care

First Virtual Cancer Clinic to Receive ASCO Certified Status

Meta-Analysis Explores Impact of Ovarian Function Suppression on Breast Cancer Recurrence and Survival

B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic GVHD

FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma

Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants